Close

AGC Biologics, Asahi Kasei Enter Clinical Drug Substance Agreement

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Receptor Grade IGF-1 LR3: Expansive Research Potential

Receptor Grade IGF-1 LR3, an engineered analog of Insulin-like...

API China 2025 kicks off with Industry Buzz on Day One

At the China Import and Export Fair Complex in...

FDA Plans to Deploy AI Tools for Scientific Reviews

The US Food and Drug Administration has announced plans...

How To Select A CDMO: Focus On Client-Centered Approach

When it comes to the pharmaceutical sector, choosing the...

AGC Biologics, a global biopharmaceutical CDMO, entered a new agreement with Asahi Kasei Pharma to produce clinical drug substance for antibody-based therapies at AGC Biologics’ Seattle manufacturing site.

AGC Biologics will leverage its monoclonal antibody development and manufacturing experience to perform process transfer, process optimization, and clinical manufacturing of the Asahi Kasei Pharma drug substance.

During this clinical phase, scientists at the Seattle manufacturing site will work to support process optimization, including product qualification, process development, analytical, and regulatory document support to manufacture the product and prepare it for late phase steps.

AGC Biologics runs multiple mammalian cGMP manufacturing lines at various scales at its Seattle facility. The campus serves as a center of excellence for formulation and employs the latest fed-batch and perfusion manufacturing processes. The site also recently expanded to add a new microbial-based manufacturing line system.

“Our company has a strong history of antibody production, and we pride ourselves on offering the flexibility and the technical expertise to meet any drug substance need at this critical clinical phase,” said JB Agnus, Chief Business Officer, AGC Biologics. “We look forward to partnering with Asahi Kasei Pharma to help achieve their goals with this important project.”

Latest stories